Arthneeti

JFL Life Sciences Q2 FY27 Share Price & Earnings Call Analysis

₹10.25+4.59% today
Market cap
₹34 Cr
P/E
5.00
ROE
15.00%
PEG
0.16
Price to sales
0.26
Debt to equity
0.47
52W high / low
₹21.2 / ₹8.55
Sales growth (5Y)
32.01%
EBITDA margin
9.06%
Net profit margin
4.87%
Promoter holding
67.47%
Sales (last year)
₹131 Cr

Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does JFL Life rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹40 Cr—
620–40%Up 2%+₹51,093 Cr44.6

Sign up free to see every company in the sector ranking and track JFL Life.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of JFL Life

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

JFL Life

Shareholding breakup across reporting periods.

Dec 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +67.47%67.47%67.47%67.47%67.47%67.47%67.47%67.47%67.47%67.47%67.47%67.47%
Public +32.53%32.54%32.53%32.53%32.53%32.53%32.53%32.53%32.53%32.53%32.53%32.53%
No. of Shareholders9218738328259669971,008998991971943904

Financials of JFL Life

Quarterly Results

Quarter-by-quarter operating performance

Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +21.709.5439.5121.2511.7311.5929.9126.8463.0511.10
Expenses +20.156.4837.1019.9010.359.6627.0023.4959.549.01
Operating Profit1.553.062.411.351.381.932.913.353.512.09
OPM %7.14%32.08%6.10%6.35%11.76%16.65%9.73%12.48%5.57%18.83%
Other Income +0.020.000.000.000.000.000.010.010.040.02
Interest0.090.260.270.200.330.240.440.381.030.30
Depreciation0.110.240.240.160.360.260.270.270.270.32
Profit before tax1.372.561.900.990.691.432.212.712.251.49
Tax %13.14%25.39%23.16%25.25%86.96%48.25%10.86%25.09%26.22%25.50%
Net Profit +1.191.911.450.740.080.751.972.021.661.11
EPS in Rs0.360.580.440.220.020.230.600.610.500.34

Financials of JFL Life

Profit & Loss

Annual income statement trend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +32303334434782131131
Expenses +30283128394274120119
Operating Profit12254581212
OPM %4.2%6%7%16%9%10%10%9%9%
Other Income +000121000
Interest111211122
Depreciation000000111
Profit before tax001444699
Tax %28%29%27%26%25%13%32%26%
Net Profit +001333467
EPS in Rs0.180.210.221.170.851.001.261.942.05
Dividend Payout %0%0%0%0%0%8%0%0%

Financials of JFL Life

Balance Sheet

Capital structure and asset base

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.420.420.50811113333
Reserves55632125613
Borrowings +891716761122
Other Liabilities +31052110152239
Total Liabilities16242948495772106
Fixed Assets +25677121215
CWIP00000000
Investments00000000
Other Assets +1419234142446092
Total Assets16242948495772106

Financials of JFL Life

Cash Flows

Operating, investing and financing cash movement

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-33-62-98-4-4
Cash from Investing Activity +-1-3-2-11-60-4
Cash from Financing Activity +4-07-18-249
Net Cash Flow00-00-0-001
Free Cash Flow-40-81-92-4-8
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit-225%177%-268%41%-206%185%-31%-37%

Financials of JFL Life

Ratios

Working capital efficiency and return ratios

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days111153132215192197155148
Inventory Days215272212130149128110
Days Payable181225821876929893
Cash Conversion Cycle11583146208246254186165
Working Capital Days62774117221181124103
ROCE %12%10%23%15%11%16%18%

Continue your research

What JFL Life's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q2 FY27)

    969 crore, up from Rs. Key results statement takeaways from Wockhardt Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • P & G Health Ltd (Q2 FY27)

    Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's

  • Akums Drugs (Q2 FY27)

    Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Key investor presentation takeaways from Akums Drugs & Pharma

  • Sai Parenteral's (Q2 FY27)

    Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56). Key investor presentation takeaways from Sai Parenterals Ltd's

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.